Interleukin-17A Simoa

Interleukin 17A (IL-17, IL-17A, or CTLA8) is the founding member of the IL-17 family of cytokines, which contains six structurally similar proteins (IL-17A-F) that are derived from different cellular sources and play differing roles in inflammation. IL-17A is a proinflammatory cytokine and is a central player in immunity and host defense. Chronic activation of IL-17A is a critical driver for the immunopathogenesis of autoimmune diseases and is implicated in other chronic inflammatory conditions including some cancers. IL-17A is generated predominately by T helper 17 cells (Th17) but can also be produced by T CD8 cells, ?d T cells, NKT cells, mast cells, and neutrophils. Active IL-17A binds to the IL-17RA and IL-17RC receptor complex on non-hematopoietic cells, activating several signaling cascades to induce a variety of cytokines (IL-1?, IL-6, GM-CSF, and TNF) and chemokines promoting further activation and recruitment of immune cells. Elevated levels of serum IL-17A have been observed in patients with rheumatoid arthritis, in the synovial fluid of patients with rheumatoid arthritis, and in the serum, synovial fluid, and psoriatic lesions of patients with psoriasis. Additionally, IL-17A is highly expressed in colorectal cancer patients and has been identified as a biomarker in combination with CCL20 to potentially diagnose and monitor disease progression. These shreds of evidence support the development of biologics targeting the IL-17A/IL-17R signaling axis for clinical use where the reduction of IL-17 has resulted in remarkable success in patients with these diseases.

Swiss-Prot Accession Number: Q16552